Shree Pacetronix Limited (SHREEPAC) Fair Value & Analysis
Healthcare · IN · Market cap ₹486M
Fair value as of: Jul 6, 2026
From 24 valuation models · updated today
Share price −8.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹74.16 – ₹279.70 · fair‑value band ₹104.10 – ₹209.61 · the ₹129.50 price screens below the ₹167.69 fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Shree Pacetronix Limited (SHREEPAC) currently trades at ₹129.50, while our model-based Fair Value estimate is ₹167.69 — implying the stock looks roughly 29.5% undervalued today. We read business quality at 60/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Shree Pacetronix Limited generated revenue of ₹216M at a net margin of 14.5%. Revenue grew 25.4% year over year. It earns a return on equity of 19.7%. Net debt stands at ₹18.9M. Fundamentals as of Jul 6, 2026
Our scenario range runs from ₹104.10 (bear case) to ₹209.61 (bull case); at ₹129.50, the current price sits within that range. The share trades about 54% below its 52-week high and 82% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside — at 29%, SHREEPAC screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
Shree Pacetronix Limited, through its subsidiary, Shree Coratomic Limited, manufactures and sells implantable cardiac pacemakers in India and internationally. The company offers pacemakers, an anti-bradycardia implantable device for permanent ventricular or atrial pacing applications; and pacing leads that consist of one or more conductors insulated with a sheath of material, such as silicone rubber, polyethylene or polyurethane for use with pulse generators for long term cardiac pacing. It also provides pacing system analyzers, a dual chamber pacing system analyzer used to analyze electrode positioning in the heart of patient while implanting the permanent pacemaker. Shree Pacetronix Limited was incorporated in 1988 and is based in Pithampur, India.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Shree Pacetronix Limited reported revenue of ₹216M in FY2026 versus ₹92.3M in FY2022, a compound +23.7%/yr. Reported net income was ₹31.4M in FY2026, compounding +41.7%/yr from FY2022.
Is SHREEPAC fairly valued? → Check now
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.95 | $182.39 | -55% |
| EssilorLuxottica Société anonyme ESLOF | $190.25 | $125.65 | -34% |
| HOYA Corporation HOCPY | $168.16 | $96.16 | -43% |
| Medline Inc MDLN | $34.71 | $30.15 | -13% |
| Becton, Dickinson and Company BDX | $149.56 | $117.04 | -22% |
| Alcon Inc ALC | $66.58 | $36.99 | -44% |
| ResMed Inc R1MD34 | R$260.00 | R$32.27 | -88% |
| West Pharmaceutical Services, Inc WST | $330.92 | $114.00 | -66% |
| Terumo Corporation TRUMF | $14.62 | $12.65 | -13% |
| Straumann Holding SAUHY | $13.07 | $5.51 | -58% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shree Pacetronix Limited (SHREEPAC) undervalued?
What is the fair value of SHREEPAC?
What is the quality score of SHREEPAC?
What is the revenue of Shree Pacetronix Limited (SHREEPAC)?
What is the net profit margin of SHREEPAC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.